After rigorous quality control, we successfully obtained 28,564 cells and unambiguously distinguished them based on their classical markers, including 4,673 T cells (CD3D+, CD3E+), 4,393 NK/CTL cells (CD3D+, CD3E+, NKG7+, GNLY+, IFNG+), 4,137 normal epithelial cells (EPCAM+, PRAC1+, HOXB13+), 6,155 tumor cells (AMACR+, CACNA1D+, PCA3+), 3,548 endothelial cells (ACKR1+, PECAM1+, CLEC14A+), 1,441 B cells (MS4A1+, CD79A+), 1,112 fibroblasts (DCN+, LUM+, PTN+), 2,725 myelocytes (CD14+, CD68+, LYZ+), and 420 mast cells (TPSAB1+, CPA3+, HPGDS+) (Figures 5A-D). The gene discussed is LYZ; the disease is neoplasm.